Idexx Laboratories Inc (IDXX) — 分析摘要
Idexx Laboratories Inc(IDXX)的市值为44.51十亿美元,最近一年的营收同比增长了+10.4%。净利润率为24.6%。当前市盈率为40.6倍。
核心要点
- 营收同比变化+10.4%
- 净利润率24.6%
- 市盈率40.6倍
与IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES板块的其他公司相比,IDXX的营收增长为+10.4%,市盈率为40.6倍。
Idexx Laboratories Inc (IDXX)
更新 — ET · 来源 POLYGON
红旗与风险提示无重大红旗
基于最新财报,没有触发重大的信用、利润率或趋势红旗。
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
行业
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
员工人数
11,000
总部
WESTBROOK, ME
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。